164 related articles for article (PubMed ID: 7164053)
1. [Tamoxifen. A new antiestrogen effective against uterine neoplasms].
Iversen OE; Wilhelmsen S; Segadal E
Tidsskr Nor Laegeforen; 1982 Jul; 102(19-21):1017-8. PubMed ID: 7164053
[No Abstract] [Full Text] [Related]
2. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
Kline RC; Freedman RS; Jones LA; Atkinson EN
Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
[No Abstract] [Full Text] [Related]
3. [Treatment of metastasizing carcinoma of the uterus with gestagens].
Engeler V
Schweiz Med Wochenschr; 1971 Dec; 101(52):1906-9. PubMed ID: 5141283
[No Abstract] [Full Text] [Related]
4. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
[TBL] [Abstract][Full Text] [Related]
5. [Antiestrogen therapy of patients with uterine cancer].
Sugimura M; Terao T
Nihon Rinsho; 1994 Mar; 52(3):804-8. PubMed ID: 8164386
[TBL] [Abstract][Full Text] [Related]
6. [Progestins in combined treatment of endometrial cancer].
Voznyĭ EK; Titova VA
Sov Med; 1990; (9):102-7. PubMed ID: 2148437
[No Abstract] [Full Text] [Related]
7. [Clinovir treatment of adenocarcinoma of the uterus with lung metastases].
Stertmann WA; Hocke M; Röttger P
MMW Munch Med Wochenschr; 1983 Jul; 125(29-30):685-6. PubMed ID: 6225946
[No Abstract] [Full Text] [Related]
8. Vaginal cytologic evaluation as a practical link between hormone blood levels and tumor hormone dependency in exclusive medroxyprogesterone treatment of recurrent or metastatic endometrial adenocarcinoma.
Bonte J; Decoster JM; Ide P
Acta Cytol; 1977; 21(2):218-24. PubMed ID: 266331
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.
Weiselberg L; Budman D; Vinciguerra V; Schulman P; Degnan TJ
Cancer Clin Trials; 1981; 4(2):195-8. PubMed ID: 7249256
[TBL] [Abstract][Full Text] [Related]
10. [Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma].
Leung F; Terzibachian JJ; Govyadovskiy A; Bourtembourg A; Maillet R; Riethmuller D
Gynecol Obstet Fertil; 2009 May; 37(5):447-51. PubMed ID: 19394886
[TBL] [Abstract][Full Text] [Related]
11. [Tamoxifen for metastatic pancreatic adenocarcinoma: a complete response].
Lamy R; Conroy T; Brunaud L; Bresler L
Gastroenterol Clin Biol; 2001 Oct; 25(10):912-3. PubMed ID: 11852397
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen in advanced and recurrent uterine sarcomas: a phase II study. Gynecological Group, Clinical Oncological Society of Australia and the Cancer Institute, Melbourne, Australia.
Cancer Treat Rep; 1986 Jun; 70(6):811-2. PubMed ID: 3731142
[No Abstract] [Full Text] [Related]
13. Endometrial carcinoma insensitive to progestin and cytotoxic chemotherapy may respond to tamoxifen.
Kauppila A; Vihko R
Acta Obstet Gynecol Scand; 1981; 60(6):589-90. PubMed ID: 6461159
[No Abstract] [Full Text] [Related]
14. Aggressive endometrial stromal sarcoma responding to medroxyprogesterone following failure of tamoxifen and combination chemotherapy. Case report.
O'Brien AA; O'Briain DS; Daly PA
Br J Obstet Gynaecol; 1985 Aug; 92(8):862-6. PubMed ID: 4027213
[No Abstract] [Full Text] [Related]
15. Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone.
Quinn MA; Campbell JJ; Murray R; Pepperell RJ
Aust N Z J Obstet Gynaecol; 1981 Nov; 21(4):226-9. PubMed ID: 6951563
[TBL] [Abstract][Full Text] [Related]
16. Cytologic evaluation of exclusive medroxyprogesterone acetate treatment for vaginal recurrence of endometrial adenocarcinoma.
Bonte J; Drochmans A; Ide P
Acta Cytol; 1970 May; 14(5):353-6. PubMed ID: 5284269
[No Abstract] [Full Text] [Related]
17. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Slavik M; Petty WM; Blessing JA; Creasman WT; Homesley HD
Cancer Treat Rep; 1984 May; 68(5):809-11. PubMed ID: 6722836
[No Abstract] [Full Text] [Related]
18. [Effects of medroxyprogesterone (MAP) therapy on the DNA content in adenocarcinoma of the human endometrium].
Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S
Minerva Ginecol; 1979; 31(7-8):597-603. PubMed ID: 481819
[No Abstract] [Full Text] [Related]
19. Tamoxifen and breast cancer prevention: are we aware of the risks?
Mandeville R; Houde M
Cancer Prev Control; 1997; 1(1):66-72. PubMed ID: 9765729
[No Abstract] [Full Text] [Related]
20. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma.
Bonte J; Ide P; Billiet G; Wynants P
Gynecol Oncol; 1981 Apr; 11(2):140-61. PubMed ID: 6783481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
